Blog | bit.bio | CEO views

CEO views

Synbio and the opportunity within the UK’s innovation landscape

Mark Kotter, CEO shares his thoughts on Synbio and how the UK can support and expand this sector and become a powerhouse of science & innovation.

09.03.2023

Published by bit.bio

Mark Kotter, CEO shares his thoughts on Synbio and how the UK can support and expand this sector and become a powerhouse of science & innovation.

Published by bit.bio

Read now

CEO views

The next disruptive technology in medicine: human biology

Our CEO explains human cells as biological computers and how this concept will impact healthcare from drug discovery to new therap...

05.01.2023

Published by bit.bio

Read now

CEO views

Going for growth by delivering the UK Science Superpower ambitions

In this blog for the BioIndustry Association, our CEO reflects on the opportunity for UK biotech to drive innovation and growth.

15.12.2022

Published by BIA

Read now

CEO views

Reflecting on UKRI’s first five year strategy

In this blog post for the BioIndustry Association, our CEO reflects on UK Research and Innovation's 2022 strategy.

05.05.2022

Published by BIA

Read now

CEO views

SynBio: the opportunity for UK Life Sciences

Our CEO writes about the importance of the synthetic biology industry as part of the UK Life Sciences vision. This was first publi...

04.03.2022

Published by BIA

Read now

CEO views

Business and academia - the perfect partners to achieve SDGs

Our CEO reflects on a recent UN High-Level Political Forum discussion about industry & academia collaborations to achieve sustaina...

27.07.2021

Published by Medium

Read now

CEO views

Why did I start a healthcare and cultured meat company?

Our CEO explains how our opti-ox technology underpins not only bit.bio but also Meatable - a cultured meat company — and why we ne...

26.04.2021

Published by Medium

Read now

Blog | CEO views